Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials

@article{Aboagye2011RecommendationsFM,
  title={Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials},
  author={Eric Ofori Aboagye and Fiona J. Gilbert and Ian N Fleming and Ambros J. Beer and Vincent J. Cunningham and Paul K. Marsden and Dimitris Visvikis and A. de Gee and Ashley M. Groves and Laura M. Kenny and Gary J. Cook and Paul E. Kinahan and Melvyn Myers and Larry C Clarke},
  journal={European Radiology},
  year={2011},
  volume={22},
  pages={1465-1478}
}
The evaluation of drug pharmacodynamics and early tumour response are integral to current clinical trials of novel cancer therapeutics to explain or predict long term clinical benefit or to confirm dose selection. Tumour vascularity assessment by positron emission tomography could be viewed as a generic pharmacodynamic endpoint or tool for monitoring response to treatment. This review discusses methods for semi-quantitative and quantitative assessment of tumour vascularity. The radioligands and… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 93 references

89Zrbevacizumab PETof early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922

  • WB Nagengast, MA de Korte, TH Oude Munnink
  • Journal of Nuclear Medicine: Official Publication…
  • 2010
Highly Influential
3 Excerpts

Errors in serial PET SUV measurements

  • R Doot, K Allberg, P Kinahan
  • J Nucl Med
  • 2010
2 Excerpts

Similar Papers

Loading similar papers…